INTRODUCTION: Patient Support Programs (PSP) from the pharmaceutical industry adds on resources to the patient care process. During the pandemic period diabetic patients were at risk of metabolic disorder for the financial restrictions to pay their medicines or for delaying their medical attention.

OBJECTIVES: We analyzed the coverage of a diabetes support program implemented in Mexico since 2018 to 2023.

METHODS: Novo-me (Novo YO, in Spanish) is a PSP which provides the first Glucagon-Like Peptide 1 receptor agonist (GLP-1) of the producer lab. Since then adds the newer options of GLP-1 in order to offer the best pharmacological treatments to the patients. We analyzed the number of patients included into the program and the given medicines by patient at national and regional level in 3 periods: prepandemic (2018 to 2019), pandemic (2020-2022), postpandemic (January 2023-Actually). Besides, we analyzed the equity of the program comparing their richest provinces versus the poorest.

RESULTS: In 2018 the program supported 483 patients, covering 81.2% (n=26/32) of the mexican provinces. Since then, it folds 85 times times (n=42,081 patients) and covers the whole country. Interestingly, the number of given treatments and province coverage grows every year; independently of the prepandemic (408%; 5342 packs) or pandemic period (3,257%: 216, 612 packs). Actually, in the postpandemic period the PSP covers 60% of the previous year. Prominently, poorest provinces were covered in the whole period; even in 2020 and 2022 when the national supply decay, there was the same reduction into the poorest versus the richest provinces (18% vs 17%).

CONCLUSIONS: PSP collaborated to provide medicines and services even in adverse conditions. In 5.5 years the program reach more people with more innovative treatments and a equitable performance in a large middle-income country. Collaboration between pharmaceutical industry and health care providers is needed not just in pandemic.